Closing the uACR screening gap.

Early CKD detection saves lives.

Diabetes is a leading cause of chronic kidney disease (CKD), and many patients have kidney damage without symptoms, making annual screening essential for early intervention and slowing disease progression. The HEDIS® Kidney Health Evaluation for Patients with Diabetes (KED) measure assesses whether adults with diabetes receive this recommended annual screening—consisting of both estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (uACR) tests. Together, these tests provide a complete picture of kidney health and support early CKD identification and better outcomes. 

The eGFR blood test measures kidney function, helps stage CKD, and guides medication dosing. The uACR urine test detects early kidney damage (albuminuria), often before eGFR declines. 

Challenges to meeting the uACR measure.

Historically, uACR completion has lagged behind eGFR. To meet the uACR component of the KED measure, both urine albumin (CPT 82043) and urine creatinine (CPT 82570) must be captured. Common challenges include billing only for urine albumin and difficulty obtaining urine samples.

Tips for improving uACR completion.

• Use standing orders or lab panels that include uACR.
• Add EHR reminders specifically for uACR.
• Encourage patients to complete urine testing.
• Use simple interventions, such as offering a cup of water while patients wait.